CervoMed Inc. Research and Development in Process
CervoMed Inc. (CRVO) reported Research and Development in Process of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-03-24
- CervoMed Inc. research and development in process for the quarter ending 2016-12-31 was $0.00.
- CervoMed Inc. research and development in process for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- CervoMed Inc. research and development in process for fiscal 2021 was $8.64M.
- CervoMed Inc. research and development in process for fiscal 2020 was $0.00.
- CervoMed Inc. research and development in process for fiscal 2016 was $951.00K.
| Period end | Research and Development in Process 3 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-24 | ||
| 2021-12-31 | $8.64M 10-K · filed 2023-03-24 | ||
| 2020-12-31 | $0.00 10-K · filed 2022-03-18 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $951.00K 10-K · filed 2018-04-02 | |
| 2016-09-30 | $951.00K 10-Q · filed 2017-11-13 | ||
| 2015-12-31 | $0.00 10-K · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |